While precision medicine has focused on tumor biology, this research suggests a broader "precision care" approach is needed. This involves tailoring treatment, such as drug dosage, based on patient-specific factors like physiology, functional reserve, and personal goals, not just genomic markers.

A PSA doubling time of less than three months acts as a surrogate marker for death from prostate cancer. This powerful heuristic doesn't predict exact lifespan, but it signifies that the cancer's mortality risk has surpassed all other potential causes of death for that individual, signaling extreme high risk.

Many childhood cancer survivors do not receive lifelong specialized follow-up, yet they face significantly increased health risks decades later. The solution is not to keep all patients in specialist clinics, but to build stronger relationships with primary care providers by equipping them with treatment summaries, screening guidelines, and open lines of communication.

For an older patient population, the ultimate goal in prostate cancer treatment might not be a traditional cure, but rather turning it into a quiescent, chronic disease manageable with well-tolerated therapy, similar to HIV. This reframes success as long-term control until a patient dies of other causes.

A patient's disease stage fundamentally changes their risk calculus. In the metastatic setting, where the primary goal is survival, patients willingly endure significant toxicity as long as their cancer is controlled. In the adjuvant (curative) setting, the long-term impact of that same toxicity becomes a more critical factor.

A critical gap exists in cancer care where cardiovascular risk factors are often ignored. As cancer treatments improve survival, patients are increasingly dying from preventable heart attacks and strokes, necessitating the specialized field of cardio-oncology.

Generic advice like "diet and exercise" is ineffective for cancer patients. Clinicians should adopt a pharmaceutical model, prescribing specific types and "doses" of diet and exercise based on a patient's unique metabolic profile, treatment, and clinical goals, rather than handing out a generic brochure.

Even when testing drugs in heavily pre-treated patients, clinical trials incorporate subtle biological selection criteria. For instance, the COMPASS trial excludes patients with visceral metastases, a tactic to enrich for a population more likely to respond and avoid the most aggressive disease subtypes.

A VA study using real-world data confirms that androgen receptor pathway inhibitors (ARPIs) combined with ADT significantly improve survival in elderly (>75), frail, and high-comorbidity prostate cancer patients. This evidence directly addresses clinician hesitancy to treat these vulnerable populations with standard-of-care combination therapy.